Research Library
Tap to Pause Rotation
N-acetylated heptapeptide (Ac-LKKTETQ), thymosin β4 fragment 17-23
Recovery & Healing

TB-500

Synthetic fragment studied for actin regulation, cell migration, and tissue repair signaling.

Mechanism of Action

Bioregulator compound with targeted biochemical activity.

Evidence Chain

TB-500

COMPOUND

1 Research Goal

• Injury & Wound Healing

Evidence Strength

Clinical Trial

11 articles sourced

Knowledge Graph

(12 connections)
CompoundGoalArticleArticleArticle
Compound (Center)
Research Goal
Linked Article

Research Evidence

(11)

Ligandrol (LGD-4033): Evidence-Based Research Review

5 min

Ligandrol (LGD-4033), also known as VK5211, is a potent, non-steroidal selective androgen receptor modulator (SARM) developed for the treatment of conditions characterized by muscle wasting and osteoporosis. As a SARM, it is designed to exert anabolic effects on skeletal muscle and bone while minimi

Clinical Trial

Clomiphene Citrate: Evidence-Based Research Review

6 min

Clomiphene citrate (CC) is a non-steroidal triphenylethylene derivative classified as a Selective Estrogen Receptor Modulator (SERM). Originally developed for the induction of ovulation in women with anovulatory infertility, it has become a cornerstone of reproductive medicine. CC operates as a race

Clinical Trial

Tamoxifen Citrate: Evidence-Based Research Review

6 min

Tamoxifen citrate is a non-steroidal triphenylethylene derivative and the prototypic Selective Estrogen Receptor Modulator (SERM). Originally developed as a contraceptive, it has become a cornerstone in the treatment and prophylaxis of estrogen receptor-positive (ER+) breast cancer. Tamoxifen exhibi

Clinical Trial

Oxandrolone: Evidence-Based Research Review

6 min

Oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) is a synthetic oral anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a unique substitution of an oxygen atom for the carbon at the C-2 position in the A-ring, oxandrolone exhibits a high anabolic-

Clinical Trial

Nandrolone Decanoate: Evidence-Based Research Review

6 min

Nandrolone decanoate (ND) is a long-acting injectable ester of the anabolic-androgenic steroid (AAS) nandrolone (19-nortestosterone). Characterized by a high anabolic-to-androgenic ratio, ND has been utilized clinically for decades to treat conditions involving protein catabolism, bone density loss,

Clinical Trial

Methenolone Enanthate: Evidence-Based Research Review

6 min

Methenolone enanthate is a long-acting injectable anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a 1-methyl modification and a 2-oxo group, it exhibits a high anabolic-to-androgenic ratio and is notable for its inability to aromatize into estrogen. Origina

Clinical Trial

BPC-157 and Tissue Repair Signaling Pathways

9 min

Comprehensive review of BPC-157 mechanisms in tissue repair, angiogenesis, and mucosal healing.

Clinical Trial

Thymalin: Thymic Peptide Immunomodulation — Clinical and Translational Evidence

6 min

Thymalin is a thymus-derived peptide preparation used clinically in several countries for immunomodulation. This review summarizes the translational and clinical evidence supporting its use in immune restoration.

Peer-Reviewed

Andarine (S-4): Evidence-Based Research Review

5 min

Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the

Preclinical

Boldenone Undecylenate: Evidence-Based Research Review

6 min

Boldenone undecylenate, a synthetic derivative of testosterone originally developed for veterinary use, is a long-acting injectable anabolic-androgenic steroid (AAS). Characterized by a double bond between the C1 and C2 positions, the compound exhibits a favorable ratio of anabolic to androgenic act

Preclinical

Peptide Synergy: Tissue Recovery and Wound Healing

7 min

Evidence-based review of wound healing peptide synergy, examining angiogenesis, collagen deposition, and tendon repair mechanisms.

Review

Overview

TB-500 is a synthetic peptide fragment representing a key active sequence of thymosin beta-4 (TMSB4X), a naturally occurring 43-amino-acid protein. The TB-500 peptide (typically 17-23 amino acids in length) captures the actin-binding domain of thymosin beta-4, which is responsible for many of its tissue-repair properties. Originally developed for equine and racing applications, TB-500 has become a prominent subject in tissue repair and regenerative medicine research.

Mechanism of Action

TB-500's primary mechanism involves the sequestration of G-actin monomers, regulating the dynamic polymerization and depolymerization of the actin cytoskeleton — a critical process in cell migration, wound healing, and tissue remodeling. By modulating actin dynamics, TB-500 promotes endothelial cell migration, keratinocyte migration, and fibroblast activity. It also upregulates VEGF expression, promoting angiogenesis in damaged tissue. Additionally, TB-500 demonstrates anti-inflammatory effects through modulation of inflammatory cytokine production and cellular immune responses.

Research Highlights

Animal studies have demonstrated TB-500's efficacy in promoting wound healing, reducing scar tissue formation, and accelerating recovery from muscle, tendon, and ligament injuries. Research has shown cardioprotective effects, with TB-500 reducing damage and improving recovery in models of myocardial infarction. Studies have explored its potential in corneal healing, dermal wound repair, and treatment of chronic inflammatory conditions. TB-500 has been shown to promote cell migration and tissue remodeling in multiple organ systems, with effects observed within days of administration in some models.

Dosage & Administration

In research and veterinary applications, TB-500 has been administered via subcutaneous injection at doses typically ranging from 2-5 mg per week, often divided into multiple administrations. Loading phases of 4-6 weeks followed by maintenance phases have been described in research literature. No standardized human dosing protocols exist. For research use only (RUO).

Safety Profile

Preclinical studies have reported favorable safety profiles, with no significant adverse effects at therapeutic doses. Long-term safety data in humans is absent. As an investigational peptide, contraindications and drug interactions have not been fully characterized. Not approved by the FDA for any indication.

References

Goldstein AL, et al. Thymosin beta4: a novel peptide for tissue repair. Ann N Y Acad Sci. 2010. Philp D, et al. Thymosin beta4 and wound healing. Expert Opin Biol Ther. 2007. Bock-Marquette I, et al. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2007. All content is for educational and research purposes only.

FDA 2026 Regulatory Update

As of April–June 2026, this compound was among the 14 peptides formally removed from the FDA's Category 2 restricted compounding list following review by the Pharmacy Compounding Advisory Committee (PCAC). This regulatory shift permits licensed compounding pharmacies to produce and dispense this compound under appropriate oversight, subject to final 503A Bulks List adjudication expected following the July 23–24, 2026 PCAC meeting. This does not constitute FDA approval for therapeutic use. All information on this page is for research purposes only.

Synergy & Compatibility

(5)

Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.

View full comparison matrix

Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.

Community Observations

(0)

Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.

No approved observations yet. Sign in to contribute.

Research Use Only

For research use only. Not medical advice.

ARIA · Sign in to chat